Comments on DEA’s proposed rule on manufacturing and procurement quotas - brookings.edu
DEA proposed new manufacturing and procurement quotas affecting controlled substances; comments are being solicited.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical manufacturers dealing with controlled substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments due by the specified deadline in the final rule announcement (not provided).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New proposed quotas for manufacturing and procurement of controlled substances.
Who it affects
All pharmaceutical manufacturers dealing with controlled substances.
What you must do
Review the proposed rule and submit comments to the DEA.
Deadline
Comments due by the specified deadline in the final rule announcement (not provided).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- May 11, 2026: Connecticut AG’s crackdown leads to major platform halting sales of “research grade” weight loss chemicals to U.S. - safemedicines.org
- Senate Unanimously Passes Boscola-Backed Legislation to Modernize Pharmaceutical Licensing - pasenate.com
- USFDA flags 3 manufacturing compliance lapses at Lupin's New Jersey unit - Business Standard
- Arkansas passes law banning PBMs from owning pharmacies - Healthcare Dive
- State Marijuana Products Can Not Enter Schedule III Without Demonstrating the Chemical Consistency Required by Federal Regulation - newswire.com